Payment overview · 2025
General Payments
$598.78
18 reported records · 8 companies
Healthcare provider profile · identity verified
Thomas A Bragg, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MOBERLY, MO · NPI 1790891885
Verified facts
What the public records show
CMS Open Payments records show Thomas A Bragg, D.O. received $598.78 in general payments during 2025 across 18 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $201.95 | 33.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.00 | 26.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.99 | 17.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $50.18 | 8.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.99 | 4.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.82 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.85 | 3.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.00 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.83 | 17 |
| Education | $99.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $102.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.50 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $79.46 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.18 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $50.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 49 |
| Losartan Potassium | Losartan Potassium | 175 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 158 | 33 |
| Lisinopril | Lisinopril | 139 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 30 |
| Celecoxib | Celecoxib | 131 | 27 |
| Potassium Chloride | Potassium Chloride | 122 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 23 |
| Montelukast Sodium | Montelukast Sodium | 111 | 24 |
| Metformin Hcl | Metformin Hcl | 110 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 28 |
| Simvastatin | Simvastatin | 109 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 24 |
| Furosemide | Furosemide | 94 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 19 |
| Gabapentin | Gabapentin | 86 | 14 |
| Pregabalin | Pregabalin | 83 | 22 |
| Lorazepam | Lorazepam | 82 | 23 |
| Omeprazole | Omeprazole | 81 | 20 |
| Farxiga | Dapagliflozin Propanediol | 70 | 12 |
| Eliquis | Apixaban | 65 | 11 |
| Finasteride | Finasteride | 65 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 11 |
| Trazodone Hcl | Trazodone Hcl | 62 | 14 |
| Sertraline Hcl | Sertraline Hcl | 61 | 14 |
| Allopurinol | Allopurinol | 54 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 51 | 38 |
| Meloxicam | Meloxicam | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Glimepiride | Glimepiride | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Carvedilol | Carvedilol | 42 | 12 |
| Cefdinir | Cefdinir | 42 | 33 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 28 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Prednisone | Prednisone | 27 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lexapro | Escitalopram Oxalate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $598.78 · 18 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, AUSTEDO XR, BREZTRI, FARXIGA, JARDIANCE, Kerendia, Ozempic, Senza, The Cologuard Plus Collection Kit, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error